跳至主要内容
临床试验/NCT02618148
NCT02618148已完成4 期

The Natural Ingredients and Artificial Made Ready, a Good Combination Reduced the Risk of Thrombosis, Concerns With Their Use of HRT

Trieu, Nguyen Thi, M.D.3 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2009年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
60
试验地点
3
主要终点
Time to Estradiol > 35 pg / ml

研究概览

简要总结

The purpose of this study is to determine whether Hormone Replacement Therapy (HRT), safety studies are combined with herbal (garlic oil, rutin, and nattokinase) to reduce estrogen side effects. Making it safer when an endocrine supplement is needed for estrogen deficiency symptoms in menopausal and postmenopausal women.

详细描述

Recent studies have proved :

-Garlic oil as garlic may reduce platelet aggregation, patients taking anticoagulant medication are cautioned about consuming garlic.

A 2013 meta-analysis concluded that garlic preparations may effectively lower total cholesterol by 11-23 mg/dL and LDL cholesterol by 3-15 mg/dL in adults with high cholesterol if taken for longer than two months. The same analysis found that garlic had a marginally positive effect on HDL cholesterol, no significant effect on blood triglyceride levels, and that garlic preparations were generally well tolerated with very few side effects.

  • Nattokinase Nattō is made from fermented soybeans and has been eaten in Japan for about a thousand years. Nattō is produced by fermentation by adding the bacterium Bacillus natto to boiled soybeans. Nattokinase is produced by the bacterium acting on the soybeans . While other soy foods contain enzymes, it is only the nattō preparation that contains the specific nattokinase enzyme.
  • Estradiol valerate is one of the most widely used esters of estradiol.
  • Progesterone: Hormone replacement therapy. Progesterone is combined with 17-beta estradiol in the estrogen patch.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Single (Care Provider)

入排标准

年龄范围
35 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in perimenopausal and postmenopausal women.
  • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

排除标准

  • Known, past or suspected breast cancer;
  • Known or suspected oestrogen-dependent malignant tumours (eg endometrial cancer);
  • Undiagnosed genital bleeding;
  • Untreated endometrial hyperplasia;
  • Previous or current venous thromboembolism (deep venous thrombosis,pulmonary embolism)
  • Known thrombophilic disorders (eg protein C, protein S, or antithrombin deficiency, see section.
  • Active or recent arterial thromboembolic disease (eg angina, myocardial infarction);
  • Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal;
  • Known hypersensitivity to the active substances or to any of the excipients;

研究组 & 干预措施

ESTROGEN HERBALS 21

Experimental

Used for women who wish to monthly menstruation

Applies to the following strengths:

17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days.

干预措施: ESTROGEN HERBALS 21 (Drug)

ESTROGEN HERBALS 28

Experimental

Used for women who do not wish to monthly menstruation

Applies to the following strengths:

17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days.

干预措施: ESTROGEN HERBALS 28 (Drug)

结局指标

主要结局

Time to Estradiol > 35 pg / ml

时间窗: 1 years

* Patients fulfilling inclusion and exclusion criteria. * Measure the time to Estradiol \> 35 pg / ml * Will be divided into two groups Group (A): Females premenopausal Group (B): Females postmenopausal * Females premenopausal: (Reference Range: (35-525 pg/mL) * Females postmenopausal: (Reference Range:(0-35 pg/mL)

次要结局

  • Time to Estradiol > 35 pg / ml(2 years)

研究者

发起方
Trieu, Nguyen Thi, M.D.
申办方类型
Indiv
责任方
Principal Investigator
主要研究者

Nguyen Thi Trieu, MD

Sponsor

Trieu, Nguyen Thi, M.D.

研究点 (3)

Loading locations...

相似试验